Skip to main navigation
Logo

Investor FAQ

Investor FAQ

Show all

COMPANY

Where is Ultragenyx's corporate headquarters?
Ultragenyx is located in Novato, California, which is in the San Francisco Bay Area. The address of our corporate headquarters is 60 Leveroni Court, Novato, CA 94949. The main phone number is (415) 483-8800. 
Where is the company incorporated?
Ultragenyx is incorporated in the state of Delaware. 
When is Ultragenyx's fiscal year-end?
 December 31st.
How is Ultragenyx's stock traded?
Ultragenyx trades on the NASDAQ Global Select Market under the symbol “RARE”.
Who is Ultragenyx's transfer agent?
American Stock Transfer & Trust Company, LLC
620 15th Avenue
Brooklyn, NY 11219  
Who is Ultragenyx's auditor?
Ernst & Young LLP
275 Shoreline Drive #600
Redwood City, CA 94065
Whom do I contact with questions about my stock?
You can contact Ultragenyx’s investor relations department by emailing ir@ultragenyx.com or by calling 1-844-758-7273.
Investors

    Investor Relations

    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • SEC Filings
    • Stock Information
    • Analyst Coverage
    • Investor FAQ
    • Contact Us

    Shareholder Tools

    • Email Alerts
    • Print
    • Share

  • Facebook
  • LinkedIn
  • Twitter
  • RSS
  • About
    • Management
      • Emil D. Kakkis, M.D., Ph.D.
      • Jayson Dallas, M.D.
      • Dennis Huang
      • Thomas Kassberg
      • Karah Parschauer
      • John Pinion
      • Shalini Sharp
    • Board of Directors
      • Daniel G. Welch
      • Emil D. Kakkis, M.D., Ph.D.
      • William Aliski
      • Deborah Dunsire, M.D.
      • Lars Ekman, M.D., Ph.D.
      • Matthew K. Fust
      • Michael Narachi
      • Clay B. Siegall, Ph.D.
    • Grants & Charitable Contributions
    • Our Commitment to Patients
    • Message from BIO
  • Medicines
    • Crysvita®
    • Mepsevii®
    • Dojolvi®
    • Dojolvi™ for Canada
    • DojolviMC–Français Canadien
  • Pipeline
    • DTX 301 for OTC
    • DTX 401 for GSDIa
  • For Patients
    • XLH
    • TIO
    • MPS 7
    • LC-FAOD
    • OTC
    • GSD1a
    • Access to Approved Therapies
    • Access to Investigational Therapies
  • Investors

      Investors

      • Press Releases
      • Events & Presentations
      • Corporate Governance
      • SEC Filings
      • Stock Information
      • Analyst Coverage
      • Investor FAQ
      • Contact Us
  • Careers
    • Culture
    • Benefits
    • Talent Network
    • Jobs
  • Partnering
    • Current Partnerships
  • Contact
  • About
    • Management
      • Emil D. Kakkis, M.D., Ph.D.
      • Jayson Dallas, M.D.
      • Dennis Huang
      • Thomas Kassberg
      • Karah Parschauer
      • John Pinion
      • Shalini Sharp
    • Board of Directors
      • Daniel G. Welch
      • Emil D. Kakkis, M.D., Ph.D.
      • William Aliski
      • Deborah Dunsire, M.D.
      • Lars Ekman, M.D., Ph.D.
      • Matthew K. Fust
      • Michael Narachi
      • Clay B. Siegall, Ph.D.
    • Grants & Charitable Contributions
    • Our Commitment to Patients
    • Message from BIO
    • Medicines
      • Crysvita®
      • Mepsevii®
      • Dojolvi®
      • Dojolvi™ for Canada
      • DojolviMC–Français Canadien
  • Pipeline
    • DTX 301 for OTC
    • DTX 401 for GSDIa
  • For Patients
    • XLH
    • TIO
    • MPS 7
    • LC-FAOD
    • OTC
    • GSD1a
    • Access to Approved Therapies
    • Access to Investigational Therapies
  • Investors

      Investors

      • Press Releases
      • Events & Presentations
      • Corporate Governance
      • SEC Filings
      • Stock Information
      • Analyst Coverage
      • Investor FAQ
      • Contact Us
  • Careers
    • Culture
    • Benefits
    • Talent Network
    • Jobs
    Partnering
    • Current Partnerships
    Contact
    • Driving Directions
  • Privacy Policy
© 2021 Ultragenyx Pharmaceutical Inc.Website Design: Hane Chow, Inc.
  • Privacy Policy
  • Cookie Policy